Moreover, it is also worth noting that most of the available animal models of Parkinson’s disease based on AAV-mediated expression of alpha-synuclein (reviewed in Marmion and Kordower, 2018) are intended to recapitulate early -even prodromal- disease stages, in order to generate a time window large enough to accommodate disease-modifying therapeutics (either gene therapy-related or unrelated). This evidence concerns the gene SNCA and Parkinson disease.